Skocz do pozycji: 1.

Tytuł:

Comparison of the Molecular International Prognostic Scoring System (IPSS-M) and Revised International Prognostic Scoring System (IPSS-R) in predicting the prognosis of patients with myelodysplastic neoplasms treated with decitabine.

Autorzy:

Nguyen, Quang Hao
Vu, Minh Phuong
Tran, Tuan Anh
Duong, Quoc Chinh
Vu, Duc Binh
Nguyen, Ha Thanh
Bach, Quoc Khanh

Pokaż więcej

Źródło:

Oncologie (De Gruyter). Mar2024, Vol. 26 Issue 2, p323-328. 6p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 2.

Tytuł:

The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.

Autorzy:

Li Y; Renmin Hospital of Wuhan University, Wuhan, China.
Mao X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-fang Avenue, Wuhan, 430030, Hubei, China.
Li M; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-fang Avenue, Wuhan, 430030, Hubei, China.
Li L; Xinqiao Hospital of Army Medical University, Chongqing, China.
Tong X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-fang Avenue, Wuhan, 430030, Hubei, China.
Huang L; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-fang Avenue, Wuhan, 430030, Hubei, China. .

Pokaż więcej

Źródło:

Clinical epigenetics [Clin Epigenetics] 2024 Jan 22; Vol. 16 (1), pp. 16. Date of Electronic Publication: 2024 Jan 22.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

DNA Methylation*
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Humans ; Decitabine/pharmacology ; Decitabine/therapeutic use ; Area Under Curve ; Computational Biology ; Pathologic Complete Response ; Neoplasm Proteins

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 3.

Tytuł:

Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study.

Autorzy:

Guo Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Guo D; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Kong D; Department of Hematology, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Bian S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
Lin L; Department of Hematology, Yantai Yuhuangding Hospital, Qingdao University Medical College, Yantai, People's Republic of China.
Fan S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Q; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Zhao Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Jiang Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Yan J; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Wang Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Sun L; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2219930.

Typ publikacji:

Journal Article

MeSH Terms:

Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Azacitidine*/adverse effects
Histone Deacetylase Inhibitors*/adverse effects
Leukemia, Myeloid, Acute*/metabolism
Antimetabolites, Antineoplastic*/adverse effects
Adult ; Humans ; Cytarabine/therapeutic use ; Decitabine/adverse effects ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 4.

Tytuł:

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics.

Autorzy:

Javorniczky NR; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Grishina O; Clinical Trials Unit, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Hund I; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Pantic M; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Pfeifer D; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Schmoor C; Clinical Trials Unit, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Thomas J; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Duyster J; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Freiburg, Freiburg, Germany.
Becker H; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Freiburg, Freiburg, Germany.
Lübbert M; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany. .

Pokaż więcej

Źródło:

Clinical epigenetics [Clin Epigenetics] 2023 Nov 28; Vol. 15 (1), pp. 185. Date of Electronic Publication: 2023 Nov 28.

Typ publikacji:

Case Reports; Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Tretinoin*/pharmacology
Tretinoin*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Humans ; Aged ; Decitabine/pharmacology ; Decitabine/therapeutic use ; DNA Methylation ; Prognosis ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 5.

Tytuł:

MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.

Autorzy:

Zhang H; Fels Institute for Cancer Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Huang C; Fels Institute for Cancer Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
Gordon J; Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia, PA, 19140, USA.
Yu S; Fels Institute for Cancer Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
Morton G; Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia, PA, 19140, USA.
Childers W; Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia, PA, 19140, USA.
Abou-Gharbia M; Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia, PA, 19140, USA.
Zhang Y; Fels Institute for Cancer Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA.
Jelinek J; Fels Institute for Cancer Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.; Coriell Institute for Medical Research, 403 Haddon Avenue, Camden, NJ, 08103, USA.; Cooper Medical School at Rowan University, Camden, NJ, 08103, USA.
Issa JJ; Fels Institute for Cancer Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA. .; Coriell Institute for Medical Research, 403 Haddon Avenue, Camden, NJ, 08103, USA. .; Cooper Medical School at Rowan University, Camden, NJ, 08103, USA. .

Pokaż więcej

Źródło:

Clinical epigenetics [Clin Epigenetics] 2024 Jan 03; Vol. 16 (1), pp. 3. Date of Electronic Publication: 2024 Jan 03.

Typ publikacji:

Journal Article; Research Support, N.I.H., Extramural

MeSH Terms:

Cyclin-Dependent Kinase 9*/genetics
Cyclin-Dependent Kinase 9*/metabolism
Leukemia, Myeloid, Acute*/genetics
Humans ; Mice ; Rats ; Animals ; Decitabine/pharmacology ; DNA Methylation ; Cell Line, Tumor ; Apoptosis

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 6.

Tytuł:

PD-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature.

Autorzy:

Han X; Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, PLA Blood Disease Center, Chongqing Key Discipline of Medicine, Chongqing, China.
Liu X
Zhang C
Wen Q
Zhang X

Pokaż więcej

Źródło:

Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Dec 01; Vol. 19 (6), pp. 1680-1684. Date of Electronic Publication: 2023 Dec 28.

Typ publikacji:

Review; Case Reports; Journal Article

MeSH Terms:

Lymphoma, T-Cell, Peripheral*/diagnosis
Lymphoma, T-Cell, Peripheral*/drug therapy
Lymphoma, T-Cell, Peripheral*/pathology
Antineoplastic Agents*/therapeutic use
Female ; Humans ; Adult ; Decitabine/therapeutic use ; Programmed Cell Death 1 Receptor ; Neoplasm Recurrence, Local/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 7.

Tytuł:

5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.

Autorzy:

Łuczkowska K; Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Kulig P; Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Rusińska K; Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Baumert B; Department of Hematology and Transplantology, Pomeranian Medical University, 71-252 Szczecin, Poland.
Machaliński B; Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.; Department of Hematology and Transplantology, Pomeranian Medical University, 71-252 Szczecin, Poland.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2023 Nov 26; Vol. 24 (23). Date of Electronic Publication: 2023 Nov 26.

Typ publikacji:

Journal Article

MeSH Terms:

Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Multiple Myeloma*/pathology
Humans ; Bortezomib/pharmacology ; Bortezomib/therapeutic use ; Decitabine/pharmacology ; Drug Resistance, Neoplasm/genetics ; Cell Line, Tumor ; Methylation ; Apoptosis/genetics

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 8.

Tytuł:

The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expression.

Autorzy:

Trtkova KS; Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic.
Luzna P; Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic.
Drozdkova DW; Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic.
Cizkova K; Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic.
Janovska L; Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic.
Gursky J; Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic.
Prukova D; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic.
Frydrych I; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic.
Hajduch M; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic.
Minarik J; Department of Hemato‑Oncology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic.

Pokaż więcej

Źródło:

Molecular medicine reports [Mol Med Rep] 2022 Oct; Vol. 26 (4). Date of Electronic Publication: 2022 Aug 31.

Typ publikacji:

Journal Article

MeSH Terms:

DNA (Cytosine-5-)-Methyltransferases*/genetics
DNA (Cytosine-5-)-Methyltransferases*/metabolism
Decitabine*/pharmacology
Epigenesis, Genetic*
Multiple Myeloma*/genetics
Multiple Myeloma*/metabolism
Cell Cycle Proteins/genetics ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Cyclin-Dependent Kinase Inhibitor p15/genetics ; Cyclin-Dependent Kinase Inhibitor p15/metabolism ; Cyclin-Dependent Kinase Inhibitor p16/genetics ; Cyclin-Dependent Kinase Inhibitor p16/metabolism ; DNA Methylation ; Gene Silencing ; Humans ; Interleukin-6/genetics ; Interleukin-6/metabolism ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; DNA Methyltransferase 3B

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 9.

Tytuł:

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.

Autorzy:

Zou R; College of Pharmaceutical Sciences Soochow University, The First Affiliated Hospital of Soochow University, Suzhou, China.; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Zhou X; Department Of Hematology & Oncology, Wuxi Taihu Lake Hospital, Wuxi, China.
Liu H; Department of Radiology, People's Hospital of Binhai County, Yancheng, China.
Wang P; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Xia F; Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
Kang L; School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, China.
Yu L; School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, China.
Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Jin Z; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Qu C; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

Pokaż więcej

Źródło:

Cancer research and treatment [Cancer Res Treat] 2023 Oct; Vol. 55 (4), pp. 1363-1368. Date of Electronic Publication: 2023 Jun 14.

Typ publikacji:

Case Reports

MeSH Terms:

Central Nervous System Neoplasms*
Lymphoma, Non-Hodgkin*
Receptors, Chimeric Antigen*
Humans ; Adaptor Proteins, Signal Transducing ; Brain ; Decitabine ; Programmed Cell Death 1 Receptor ; Sialic Acid Binding Ig-like Lectin 2 ; Immune Checkpoint Inhibitors/therapeutic use ; Tyrosine Kinase Inhibitors/therapeutic use

Raport

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 10.

Tytuł:

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada.

Autorzy:

Yun, John Paul (AUTHOR)
Ding, Philip Q. (AUTHOR)
Dolley, Aastha (AUTHOR)
Cheung, Winson Y. (AUTHOR)

Pokaż więcej

Źródło:

Current Oncology. Sep2023, Vol. 30 Issue 9, p8005-8018. 14p. 1 Diagram, 4 Charts, 2 Graphs.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 11.

Tytuł:

The interplay between H3K36 methylation and DNA methylation in cancer.

Autorzy:

Jiameng Dan
Zeling Du
Jinghong Zhang
Taiping Chen

Pokaż więcej

Źródło:

Cancer Biology & Medicine. Aug2023, Vol. 20 Issue 8, p545-552. 8p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 12.

Tytuł:

Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.

Autorzy:

Xu R; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Li M; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Wu P; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Deng C; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Geng S; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Huang X; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Weng J; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Du X; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 312-320.

Typ publikacji:

Journal Article; Meta-Analysis; Systematic Review

MeSH Terms:

Antimetabolites, Antineoplastic/*therapeutic use
Azacitidine/*therapeutic use
Decitabine/*therapeutic use
Leukemia, Myelomonocytic, Chronic/*drug therapy
Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Azacitidine/administration & dosage ; Azacitidine/adverse effects ; Decitabine/administration & dosage ; Decitabine/adverse effects ; Humans ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 13.

Tytuł:

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML.

Autorzy:

Li H; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Wang Y; Department of Hematology, Provincial People's Hospital, Xi'an, 710068, China.
Feng S; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Chang K; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Yu X; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Yang F; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Huang H; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Wang Y; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China.
Li X; Institute of Hematology, School of Medicine, Northwest University, Xi'an, 710069, China. .; College of Life Science, Northwest University, 229 Taibai North Road, Xi'an, 710069, Shaanxi, China. .
Guan F; Key Laboratory of Resource Biology and Biotechnology Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an, 710069, China. .; College of Life Science, Northwest University, 229 Taibai North Road, Xi'an, 710069, Shaanxi, China. .

Pokaż więcej

Źródło:

Cell communication and signaling : CCS [Cell Commun Signal] 2023 Sep 22; Vol. 21 (1), pp. 255. Date of Electronic Publication: 2023 Sep 22.

Typ publikacji:

Video-Audio Media; Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Oncogenes*
Myelodysplastic Syndromes*/drug therapy
Humans ; Decitabine/pharmacology ; N-Acetylglucosaminyltransferases ; Nuclear Proteins ; Twist-Related Protein 1

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 14.

Tytuł:

CRISPR imaging reveals chromatin fluctuation at the centromere region related to cellular senescence.

Autorzy:

Takata H; Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ikeda, Osaka, 563-8577, Japan. .
Masuda Y; Graduate School of Human Development and Environment, Kobe University, Nada-ku, Kobe, 657-8501, Japan.
Ohmido N; Graduate School of Human Development and Environment, Kobe University, Nada-ku, Kobe, 657-8501, Japan.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2023 Sep 05; Vol. 13 (1), pp. 14609. Date of Electronic Publication: 2023 Sep 05.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Chromatin*
Clustered Regularly Interspaced Short Palindromic Repeats*
Humans ; Centromere ; Cellular Senescence ; Chromosomes, Human, Pair 1 ; Decitabine

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 15.

Tytuł:

DNA methyltransferase inhibitor exposure-response: Challenges and opportunities.

Autorzy:

Kagan AB; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Garrison DA; Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Anders NM; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.
Webster JA; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.
Baker SD; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Yegnasubramanian S; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.
Rudek MA; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.

Pokaż więcej

Źródło:

Clinical and translational science [Clin Transl Sci] 2023 Aug; Vol. 16 (8), pp. 1309-1322. Date of Electronic Publication: 2023 Jun 21.

Typ publikacji:

Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

MeSH Terms:

Azacitidine*/therapeutic use
Azacitidine*/pharmacology
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Decitabine/therapeutic use ; Enzyme Inhibitors/pharmacology ; Enzyme Inhibitors/therapeutic use ; DNA Methylation ; DNA ; Methyltransferases

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 16.

Tytuł:

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes.

Autorzy:

Kim S; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.; Department of Radiological and Medico-Oncological Sciences, University of Science and Technology, Daejeon 34113, Korea.
Shin DY; Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Korea.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Korea.
Kim D; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.; Department of Radiological and Medico-Oncological Sciences, University of Science and Technology, Daejeon 34113, Korea.
Oh S; Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.
Hong J; Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Korea.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Korea.
Kim I; Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Korea.
Kim E; Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.; Department of Radiological and Medico-Oncological Sciences, University of Science and Technology, Daejeon 34113, Korea.

Pokaż więcej

Źródło:

Cells [Cells] 2021 Dec 10; Vol. 10 (12). Date of Electronic Publication: 2021 Dec 10.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Gene Expression Profiling*
Biomarkers/*metabolism
Decitabine/*therapeutic use
Drug Resistance/*genetics
Myelodysplastic Syndromes/*drug therapy
Bone Marrow/drug effects ; Bone Marrow/metabolism ; Cell Line ; Decitabine/pharmacology ; Drug Resistance/drug effects ; Gene Expression Regulation/drug effects ; Gene Ontology ; Humans ; Protein Interaction Maps/drug effects ; RNA-Seq ; Reproducibility of Results

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 17.

Tytuł:

CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.

Autorzy:

Hoffmann F; Department of Dermatology and Allergy, University Medical Center Bonn, Bonn, Germany.
Franzen A; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
de Vos L; Department of Dermatology and Allergy, University Medical Center Bonn, Bonn, Germany.; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Wuest L; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Kulcsár Z; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Fietz S; Department of Dermatology and Allergy, University Medical Center Bonn, Bonn, Germany.; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Maas AP; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Hollick S; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Diop MY; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Gabrielpillai J; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Vogt T; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Kuster P; Department of Dermatology and Allergy, University Medical Center Bonn, Bonn, Germany.
Zarbl R; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Dietrich J; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Kristiansen G; Institute of Pathology, University Medical Center Bonn, Bonn, Germany.
Brossart P; Department of Oncology, Hematology and Rheumatology, University Medical Center Bonn, Bonn, Germany.
Landsberg J; Department of Dermatology and Allergy, University Medical Center Bonn, Bonn, Germany.
Strieth S; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Dietrich D; Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. .

Pokaż więcej

Źródło:

Clinical epigenetics [Clin Epigenetics] 2023 Jul 06; Vol. 15 (1), pp. 112. Date of Electronic Publication: 2023 Jul 06.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

DNA Methylation*
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/genetics
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/genetics ; CTLA-4 Antigen/genetics ; Decitabine/pharmacology ; Decitabine/therapeutic use ; Immunotherapy/methods ; DNA

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 18.

Tytuł:

Decitabine in patients with myelodysplastic syndromes: A multi-center, open-label, dose comparison trial.

Autorzy:

Liu H; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
Jiang H; Institute of Hematology, Peking University People's Hospital, Beijing, China.
Tong H; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xia R; Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yang L; Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Zhao H; Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Ouyang J; Department of Hematology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Bai H; Department of Hematology, Lanzhou General Hospital, Lanzhou Military Area, Lanzhou, China.
Sun H; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Hou L; Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
Jiang M; Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Zeng Y; Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Liu Z; Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
Liang A; Department of Hematology/Oncology, TongJi Hospital of Tong Ji University, Shanghai, China.
Xie Y; Department of Hematology, The Shanghai Fifth People's Hospital, Fudan University, Blood Disease Research Center, Fudan University, Shanghai, China.
Yu K; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Zhai Z; Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Liu L; Department of Hematology, Tangdu Hospital, PLA Air Force Military Medical University, Xi'an, Shanxi, China.
Jia J; Institute of Hematology, Peking University People's Hospital, Beijing, China.
Fu R; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
Shao Z; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2023 Jul; Vol. 12 (13), pp. 13885-13893. Date of Electronic Publication: 2023 Jun 23.

Typ publikacji:

Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Myelodysplastic Syndromes*/drug therapy
Neutropenia*/chemically induced
Adult ; Humans ; Decitabine ; Azacitidine/adverse effects ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 19.

Tytuł:

Low-dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter.

Autorzy:

Shao X; Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Xu P; Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.; Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Ji L; Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Wu B; Department of Transfusion Medicine, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Zhan Y; Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Zhuang X; Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.; Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Ou Y; Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.; Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Hua F; Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Sun L; Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Li F; Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.
Wang X; Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.; Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen H; Department of Thoracic Surgery, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Cheng Y; Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.; Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, China.; Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai, China.

Pokaż więcej

Źródło:

Clinical and translational medicine [Clin Transl Med] 2023 Jul; Vol. 13 (7), pp. e1344.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

PPAR gamma*
Purpura, Thrombocytopenic, Idiopathic*
Animals ; Mice ; Decitabine ; Interleukin-10 ; Inflammasomes ; Leukocytes, Mononuclear ; NLR Family, Pyrin Domain-Containing 3 Protein ; Macrophages

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 20.

Tytuł:

Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.

Autorzy:

Tang Z; Hannover Medical School, Centre for Pharmacology and Toxicology, Carl-Neuberg-Str.1, 30625, Hannover, Germany.
Liu L; Hannover Medical School, Centre for Pharmacology and Toxicology, Carl-Neuberg-Str.1, 30625, Hannover, Germany.
Borlak J; Hannover Medical School, Centre for Pharmacology and Toxicology, Carl-Neuberg-Str.1, 30625, Hannover, Germany. .

Pokaż więcej

Źródło:

Clinical epigenetics [Clin Epigenetics] 2023 May 19; Vol. 15 (1), pp. 89. Date of Electronic Publication: 2023 May 19.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Adenocarcinoma*
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Humans ; Decitabine/pharmacology ; Azacitidine/pharmacology ; Histone Deacetylases ; Cytidine Deaminase ; Tumor Suppressor Protein p53 ; Prospective Studies ; DNA Methylation ; Histone Deacetylase Inhibitors/pharmacology ; Histone Deacetylase Inhibitors/therapeutic use ; Tetrahydrouridine/pharmacology ; Epigenesis, Genetic ; Cell Line, Tumor ; Tumor Microenvironment

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 21.

Tytuł:

Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.

Autorzy:

Zhang MC; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fang Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Xu PP; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Dong L; Department of Pathology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shen R; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huang YH; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fu D; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yan ZX; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cheng S; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiang XF; Department of Nuclear Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Song Q; Department of Radiology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
He Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhao Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lu M; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ye J; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liu F; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cheng L; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wang CF; Department of Pathology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wang L; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Shanghai, China.
Zhao WL; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Shanghai, China.

Pokaż więcej

Źródło:

Clinical and translational medicine [Clin Transl Med] 2021 Dec; Vol. 11 (12), pp. e584.

Typ publikacji:

Letter; Research Support, Non-U.S. Gov't

MeSH Terms:

Treatment Outcome*
Decitabine/*pharmacology
Lymphoma, Large B-Cell, Diffuse/*genetics
Tumor Microenvironment/*physiology
Aged ; Biomarkers/analysis ; Decitabine/metabolism ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/physiopathology ; Male ; Middle Aged

Raport

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 22.

Tytuł:

Decitabine activates type I interferon signaling to inhibit p53-deficient myeloid malignant cells.

Autorzy:

Wu J; State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li Y; State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wu J; State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Song H; State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tang Y; State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yan N; State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wu L; State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhang S; State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chang C; Department of Hematology, Shanghai Institute of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Lu M; State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Pokaż więcej

Źródło:

Clinical and translational medicine [Clin Transl Med] 2021 Nov; Vol. 11 (11), pp. e593.

Typ publikacji:

Letter; Research Support, Non-U.S. Gov't

MeSH Terms:

Decitabine/*pharmacology
Interferon Type I/*drug effects
Myeloid Cells/*drug effects
Cell Line/drug effects ; Decitabine/therapeutic use ; Humans ; Tumor Suppressor Protein p53/deficiency ; Tumor Suppressor Protein p53/genetics

Raport

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 23.

Tytuł:

RNautophagic regulation of DNMT3a‐dependent DNA methylation by Linc00942 enhances chemoresistance in gastric cancer.

Autorzy:

Zhu, Liyuan (AUTHOR)
Zhu, Yiran (AUTHOR)
Li, Fang (AUTHOR)
Meng, Yuan (AUTHOR)
Wang, Hanying (AUTHOR)
Xu, Wenxia (AUTHOR)
Luo, Jingfeng (AUTHOR)
Wang, Xian (AUTHOR)
Feng, Lifeng (AUTHOR)
Jin, Hongchuan (AUTHOR)

Pokaż więcej

Źródło:

Clinical & Translational Medicine. Jul2023, Vol. 13 Issue 7, p1-17. 17p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 24.

Tytuł:

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.

Autorzy:

Taib N; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Merhi M; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Inchakalody V; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Mestiri S; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Hydrose S; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Makni-Maalej K; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Raza A; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Sahir F; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Azizi F; Translational Research Institute, Academic Health System, Hamad Medical Corporation, 2030, Doha, Qatar.
Nizamuddin PB; Translational Research Institute, Academic Health System, Hamad Medical Corporation, 2030, Doha, Qatar.
Fernandes Q; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; College of Medicine, Qatar University, 2713, Doha, Qatar.
Yoosuf ZSKM; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; College of Health and Life Sciences, Hamad Bin Khalifa University, 34110, Doha, Qatar.
Almoghrabi S; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Al-Zaidan L; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar.; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Shablak A; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Uddin S; Translational Research Institute and Dermatology Institute, Academic Health System, Hamad Medical Corporation, 2030, Doha, Qatar.; Laboratory Animal Research Center, Qatar University, 2713, Doha, Qatar.
Maccalli C; Laboratory of Immune and Biological Therapy, Human Immunology Department, Research Branch, Sidra Medicine, 26999, Doha, Qatar.
Al Homsi MU; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar.
Dermime S; Translational Cancer Research Facility, National Center for Cancer Care and Research/Translational Research Institute, Hamad Medical Corporation, 2030, Doha, Qatar. .; National Center for Cancer Care and Research, Hamad Medical Corporation, 2030, Doha, Qatar. .; College of Health and Life Sciences, Hamad Bin Khalifa University, 34110, Doha, Qatar. .

Pokaż więcej

Źródło:

Journal of translational medicine [J Transl Med] 2023 Mar 31; Vol. 21 (1), pp. 235. Date of Electronic Publication: 2023 Mar 31.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Antigens, Neoplasm*/metabolism
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Male ; Humans ; Decitabine/pharmacology ; Decitabine/therapeutic use ; Membrane Proteins/genetics ; Membrane Proteins/metabolism ; Immunotherapy ; Cell Line, Tumor

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 25.

Tytuł:

DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia.

Autorzy:

He S; Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518000, China.
Li Y; Department of Hematology, Peking Third Hospital, Beijing, 100191, China.; Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.
Shi X; Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518000, China.
Wang L; Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518000, China.
Cai D; Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518000, China.
Zhou J; Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518000, China. .
Yu L; Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518000, China. .

Pokaż więcej

Źródło:

Clinical epigenetics [Clin Epigenetics] 2023 Mar 03; Vol. 15 (1), pp. 37. Date of Electronic Publication: 2023 Mar 03.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

DNA Methylation*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Humans ; Decitabine/pharmacology ; Decitabine/therapeutic use ; Genes, Regulator ; Gene Silencing ; Membrane Proteins ; Vesicular Transport Proteins

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 26.

Tytuł:

5-aza-2'-deoxycytidine induces apoptosis and inhibits tumour growth in vivo of FaDu cells, a specific HPVnegative HNSCC cell line.

Autorzy:

Miari R; Department of Human Biology, Faculty of Natural Science, University of Haifa, Haifa, Israel.
Azzam N; Department of Human Biology, Faculty of Natural Science, University of Haifa, Haifa, Israel.; MIGAL Galilee Research Institute, Kiryat Shmona, Israel.
Bar-Shalom R; Department of Human Biology, Faculty of Natural Science, University of Haifa, Haifa, Israel.
Fares F; Department of Human Biology, Faculty of Natural Science, University of Haifa, Haifa, Israel.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2021 Sep 17; Vol. 16 (9), pp. e0253756. Date of Electronic Publication: 2021 Sep 17 (Print Publication: 2021).

Typ publikacji:

Journal Article

MeSH Terms:

Antimetabolites, Antineoplastic/*administration & dosage
Decitabine/*administration & dosage
Head and Neck Neoplasms/*drug therapy
Squamous Cell Carcinoma of Head and Neck/*drug therapy
Tumor Suppressor Protein p53/*genetics
Animals ; Antimetabolites, Antineoplastic/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Decitabine/pharmacology ; Dose-Response Relationship, Drug ; Gene Expression Regulation, Neoplastic/drug effects ; Head and Neck Neoplasms/genetics ; Humans ; Male ; Mice ; Mutation ; Squamous Cell Carcinoma of Head and Neck/genetics ; Xenograft Model Antitumor Assays

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 27.

Tytuł:

The Methylation Analysis of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Locus in GH-Secreting Pituitary Adenomas.

Autorzy:

Dalle Nogare M; Department of Biology, University of Padova, 35128 Padova, Italy.
D'Annunzio S; Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy.
Vazza G; Department of Biology, University of Padova, 35128 Padova, Italy.
Regazzo D; Endocrinology Unit, Department of Medicine, Padova University Hospital, 35121 Padova, Italy.
Picello L; Department of Biology, University of Padova, 35128 Padova, Italy.
Denaro L; Academic Neurosurgery, Department of Neurosciences, Padova University Hospital, 35121 Padova, Italy.
Voltan G; Endocrinology Unit, Department of Medicine, Padova University Hospital, 35121 Padova, Italy.
Scaroni C; Endocrinology Unit, Department of Medicine, Padova University Hospital, 35121 Padova, Italy.
Ceccato F; Endocrinology Unit, Department of Medicine, Padova University Hospital, 35121 Padova, Italy.
Occhi G; Department of Biology, University of Padova, 35128 Padova, Italy.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2023 May 25; Vol. 24 (11). Date of Electronic Publication: 2023 May 25.

Typ publikacji:

Journal Article

MeSH Terms:

Adenoma*/genetics
Adenoma*/metabolism
Growth Hormone-Secreting Pituitary Adenoma*/genetics
Receptors, Gastrointestinal Hormone*/metabolism
Humans ; Decitabine ; DNA Methylation ; Epigenesis, Genetic

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 28.

Tytuł:

Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.

Autorzy:

Liu Z; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.; Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China.; Shenzhen Key Laboratory of Synthetic Genomics, Guangdong Provincial Key Laboratory of Synthetic Genomics, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 518055, Shenzhen, China.; University of Chinese Academy of Sciences, 100049, Beijing, China.; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.
Li X; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Gao Y; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Liu J; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Feng Y; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Liu Y; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Wang J; Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China.; University of Chinese Academy of Sciences, 100049, Beijing, China.
Wang C; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China.; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Wang D; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China. .; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, 310058, China. .
He J; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. .
Han W; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China. .; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China. .
Mei Q; Changping Laboratory, Yard 28, Science Park Road, Changping District, 102206, Beijing, China. .; Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, China. .
Sun Y; Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. .; Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China. .

Pokaż więcej

Źródło:

Molecular cancer [Mol Cancer] 2023 May 16; Vol. 22 (1), pp. 84. Date of Electronic Publication: 2023 May 16.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Epigenesis, Genetic*
CD8-Positive T-Lymphocytes*
Animals ; Mice ; Decitabine/pharmacology ; Immunotherapy ; Biomarkers/metabolism ; DNA Methylation ; Mice, Knockout ; Tumor Microenvironment

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 29.

Tytuł:

Characterisation of miRNA Expression in Dental Pulp Cells during Epigenetically-Driven Reparative Processes.

Autorzy:

Kearney M; Division of Restorative Dentistry & Periodontology, Dublin Dental University Hospital, Trinity College Dublin, University of Dublin, D02 F859 Dublin, Ireland.
Cooper PR; Department of Oral Sciences, Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin 9016, New Zealand.
Smith AJ; Oral Biology, School of Dentistry, University of Birmingham, Birmingham B5 7EG, UK.
Duncan HF; Division of Restorative Dentistry & Periodontology, Dublin Dental University Hospital, Trinity College Dublin, University of Dublin, D02 F859 Dublin, Ireland.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2023 May 11; Vol. 24 (10). Date of Electronic Publication: 2023 May 11.

Typ publikacji:

Journal Article

MeSH Terms:

MicroRNAs*/genetics
Dental Pulp ; Vorinostat ; Histone Deacetylase Inhibitors/pharmacology ; Azacitidine/pharmacology ; Decitabine/pharmacology ; Hydroxamic Acids/pharmacology

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 30.

Tytuł:

5-aza-2'-deoxycitidine inhibits cell proliferation, extracellular matrix formation and Wnt/β-catenin pathway in human uterine leiomyomas.

Autorzy:

Carbajo-García MC; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.; Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain.
Corachán A; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.; Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain.
Segura-Benitez M; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.; Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain.
Monleón J; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Escrig J; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Faus A; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.
Pellicer A; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.; IVIRMA Rome, Rome, Italy.
Cervelló I; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain.
Ferrero H; Fundación IVI, Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell 106, Torre A, Planta 1ª, 46026, Valencia, Spain. .

Pokaż więcej

Źródło:

Reproductive biology and endocrinology : RB&E [Reprod Biol Endocrinol] 2021 Jul 08; Vol. 19 (1), pp. 106. Date of Electronic Publication: 2021 Jul 08.

Typ publikacji:

Journal Article

MeSH Terms:

Cell Proliferation/*drug effects
Decitabine/*pharmacology
Extracellular Matrix/*drug effects
Leiomyoma/*pathology
Uterine Neoplasms/*pathology
Wnt Signaling Pathway/*drug effects
Adult ; Antimetabolites, Antineoplastic/pharmacology ; Antimetabolites, Antineoplastic/therapeutic use ; Cell Proliferation/physiology ; Cell Survival/drug effects ; Cell Survival/physiology ; DNA Methylation/drug effects ; DNA Methylation/physiology ; Decitabine/therapeutic use ; Dose-Response Relationship, Drug ; Extracellular Matrix/metabolism ; Female ; Humans ; Leiomyoma/metabolism ; Middle Aged ; Prospective Studies ; Uterine Neoplasms/metabolism ; Wnt Signaling Pathway/physiology

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 31.

Tytuł:

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.

Autorzy:

Kong X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ding M; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Feng X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Dong M; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang L; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Fu X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li L; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Sun Z; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yan J; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wang X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wu X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Chen Q; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang M; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhu L; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (7), pp. 8134-8143. Date of Electronic Publication: 2023 Jan 25.

Typ publikacji:

Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Decitabine/adverse effects ; Rituximab/therapeutic use ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 32.

Tytuł:

Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.

Autorzy:

Feld J; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tremblay D; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Navada SC; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Silverman LR; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 525-539. Date of Electronic Publication: 2022 Nov 12.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/pathology
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Decitabine/therapeutic use ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 33.

Tytuł:

Valency-Based Indices for Some Succinct Drugs by Using M-Polynomial.

Autorzy:

Ghani, Muhammad Usman (AUTHOR)
Campena, Francis Joseph H. (AUTHOR)
Pattabiraman, K. (AUTHOR)
Ismail, Rashad (AUTHOR)
Karamti, Hanen (AUTHOR)
Husin, Mohamad Nazri (AUTHOR)

Pokaż więcej

Źródło:

Symmetry (20738994). Mar2023, Vol. 15 Issue 3, p603. 13p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 34.

Tytuł:

Epigenetic Modification of MicroRNA-219-1 and Its Association with Glioblastoma Multiforme.

Autorzy:

Ghasemi A; Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, 1417613151, Iran. .
Mohammadi A; Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, 1449614535, Iran. .
Fallah S; Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, 1449614535, Iran. .

Pokaż więcej

Źródło:

Biochemistry. Biokhimiia [Biochemistry (Mosc)] 2021 Apr; Vol. 86 (4), pp. 420-432.

Typ publikacji:

Journal Article

MeSH Terms:

Epigenesis, Genetic*
Decitabine/*pharmacology
Glioblastoma/*genetics
MicroRNAs/*genetics
Adult ; Aged ; Cell Line, Tumor ; DNA Methylation ; Decitabine/therapeutic use ; Female ; Gene Expression Regulation, Neoplastic ; Glioblastoma/drug therapy ; Glioblastoma/metabolism ; Humans ; Male ; Middle Aged

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 35.

Tytuł:

DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors.

Autorzy:

Laranjeira ABA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Hollingshead MG; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Nguyen D; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Kinders RJ; Leidos Biomedical Research, Inc., Frederick, MD, USA.
Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Yang SX; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA. .; Division of Cancer Treatment and Diagnosis, National Clinical Target Validation Laboratory, 9609 Medical Center Drive, Bethesda, MD, 20892, USA. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2023 Apr 12; Vol. 13 (1), pp. 5964. Date of Electronic Publication: 2023 Apr 12.

Typ publikacji:

Journal Article; Research Support, N.I.H., Extramural

MeSH Terms:

DNA (Cytosine-5-)-Methyltransferases*/metabolism
Azacitidine*/pharmacology
Humans ; Mice ; Animals ; Decitabine/pharmacology ; DNA (Cytosine-5-)-Methyltransferase 1/genetics ; DNA Damage ; Demethylation ; DNA ; DNA Methylation ; Cell Line, Tumor

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 36.

Tytuł:

Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.

Autorzy:

Aribi A; Department Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Salhotra A; Department Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Ball B; Department Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Stein A; Department Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Marcucci G; Department Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Pullarkat V; Department Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Apr; Vol. 64 (4), pp. 897-899. Date of Electronic Publication: 2023 Feb 27.

Typ publikacji:

Letter

MeSH Terms:

Azacitidine*/therapeutic use
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Decitabine/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Remission Induction ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Opinia redakcyjna

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 37.

Tytuł:

Promoting GSDME expression through DNA demethylation to increase chemosensitivity of breast cancer MCF-7 / Taxol cells.

Autorzy:

Gong W; Zhengzhou Key Laboratory of Children's Infection and Immunity, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Fang P; Zhengzhou Key Laboratory of Children's Infection and Immunity, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Leng M; Zhengzhou Key Laboratory of Children's Infection and Immunity, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Shi Y; Clinical Laboratory, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2023 Mar 03; Vol. 18 (3), pp. e0282244. Date of Electronic Publication: 2023 Mar 03 (Print Publication: 2023).

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Breast Neoplasms*
Humans ; Female ; Paclitaxel ; DNA Demethylation ; Decitabine ; MCF-7 Cells

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 38.

Tytuł:

Mechanism of Action of Decitabine in the Treatment of Acute Myeloid Leukemia by Regulating LINC00599.

Autorzy:

Du F; Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jin T; Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wang L; Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Pokaż więcej

Źródło:

Analytical cellular pathology (Amsterdam) [Anal Cell Pathol (Amst)] 2023 Feb 22; Vol. 2023, pp. 2951519. Date of Electronic Publication: 2023 Feb 22 (Print Publication: 2023).

Typ publikacji:

Journal Article

MeSH Terms:

Leukemia, Myeloid, Acute*
MicroRNAs*
Humans ; Animals ; Mice ; Caspase 3 ; Decitabine ; Mice, Nude ; Ki-67 Antigen ; Reactive Oxygen Species

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 39.

Tytuł:

DNA Methylation as a Therapeutic Target for Bladder Cancer.

Autorzy:

Nunes SP; Cancer Biology & Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal.; Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain.; Biomedical Research Institute I+12, University Hospital '12 de Octubre', 28041 Madrid, Spain.
Henrique R; Cancer Biology & Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal.; Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal.; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), 4050-313 Porto, Portugal.
Jerónimo C; Cancer Biology & Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal.; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), 4050-313 Porto, Portugal.
Paramio JM; Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain.; Biomedical Research Institute I+12, University Hospital '12 de Octubre', 28041 Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.

Pokaż więcej

Źródło:

Cells [Cells] 2020 Aug 07; Vol. 9 (8). Date of Electronic Publication: 2020 Aug 07.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't; Review

MeSH Terms:

Antimetabolites, Antineoplastic*/pharmacology
Antimetabolites, Antineoplastic*/therapeutic use
Azacitidine*/pharmacology
Azacitidine*/therapeutic use
Decitabine*/pharmacology
Decitabine*/therapeutic use
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/metabolism
DNA Methylation/*drug effects
Epigenesis, Genetic/*drug effects
Animals ; Cell Line, Tumor ; Humans

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 40.

Tytuł:

Decitabine Treatment Induces a Viral Mimicry Response in Cervical Cancer Cells and Further Sensitizes Cells to Chemotherapy.

Autorzy:

Alexandraki A; Department of Biological Sciences, University of Cyprus, 1 University Avenue, Nicosia 2109, Cyprus.
Strati K; Department of Biological Sciences, University of Cyprus, 1 University Avenue, Nicosia 2109, Cyprus.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2022 Nov 14; Vol. 23 (22). Date of Electronic Publication: 2022 Nov 14.

Typ publikacji:

Journal Article

MeSH Terms:

Uterine Cervical Neoplasms*/drug therapy
Papillomavirus Infections*
Female ; Humans ; Decitabine/pharmacology ; B7-H1 Antigen ; HeLa Cells

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 41.

Tytuł:

Absence of early platelet increment in healthy mice during decitabine treatment.

Autorzy:

Baumann, Juliane (AUTHOR)
Spindler, Markus (AUTHOR)
Throm, Yannick (AUTHOR)
Lübbert, Michael (AUTHOR)
Bender, Markus (AUTHOR)

Pokaż więcej

Źródło:

Scientific Reports. 12/23/2022, Vol. 12 Issue 1, p1-7. 7p.

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 42.

Tytuł:

Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.

Autorzy:

Ma YY; a Department of Hematology , The Sixth Medical Center, Chinese PLA General Hospital , Beijing , People's Republic of China.
Zhao M; b Department of Nutrition , The Sixth Medical Center, Chinese PLA General Hospital , Beijing , People's Republic of China.
Liu Y; a Department of Hematology , The Sixth Medical Center, Chinese PLA General Hospital , Beijing , People's Republic of China.
Zhao DF; a Department of Hematology , The Sixth Medical Center, Chinese PLA General Hospital , Beijing , People's Republic of China.
Wang LX; a Department of Hematology , The Sixth Medical Center, Chinese PLA General Hospital , Beijing , People's Republic of China.
Chen XP; a Department of Hematology , The Sixth Medical Center, Chinese PLA General Hospital , Beijing , People's Republic of China.
Li L; a Department of Hematology , The Sixth Medical Center, Chinese PLA General Hospital , Beijing , People's Republic of China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2019 Dec; Vol. 24 (1), pp. 507-515.

Typ publikacji:

Journal Article; Meta-Analysis; Systematic Review

MeSH Terms:

Molecular Targeted Therapy*
Salvage Therapy*
Antimetabolites, Antineoplastic/*therapeutic use
DNA Methylation/*drug effects
Decitabine/*therapeutic use
Enzyme Inhibitors/*therapeutic use
Gene Expression Regulation, Leukemic/*drug effects
Leukemia, Myeloid, Acute/*drug therapy
Antimetabolites, Antineoplastic/adverse effects ; Antimetabolites, Antineoplastic/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; DNA (Cytosine-5-)-Methyltransferase 1/antagonists & inhibitors ; Decitabine/administration & dosage ; Decitabine/adverse effects ; Decitabine/pharmacology ; Enzyme Inhibitors/administration & dosage ; Enzyme Inhibitors/adverse effects ; Enzyme Inhibitors/pharmacology ; Fatigue/chemically induced ; Febrile Neutropenia/chemically induced ; Female ; Gastrointestinal Diseases/chemically induced ; Hematologic Diseases/chemically induced ; Humans ; Hyperglycemia/chemically induced ; Immunotherapy ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Recurrence ; Remission Induction

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 43.

Tytuł:

Decitabine and Cedazuridine.

Źródło:

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2020 Oct 30; Vol. 77 (22), pp. 1809-1811.

Typ publikacji:

Journal Article

MeSH Terms:

Drug Labeling*
Antineoplastic Agents/*pharmacology
Decitabine/*pharmacology
Myelodysplastic Syndromes/*drug therapy
Uridine/*analogs & derivatives
Administration, Oral ; Adult ; Antineoplastic Agents/therapeutic use ; Cytidine Deaminase/antagonists & inhibitors ; Cytidine Deaminase/metabolism ; DNA Methylation/drug effects ; DNA Modification Methylases/antagonists & inhibitors ; DNA Modification Methylases/metabolism ; Decitabine/therapeutic use ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Combinations ; Drug Interactions ; Epigenesis, Genetic/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Myelodysplastic Syndromes/genetics ; Uridine/pharmacology ; Uridine/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 44.

Tytuł:

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults​.

Autorzy:

Yoo KH; Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Cho J; Division of Hematology-Oncology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea.
Han B; Division of Hematology/Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Kim SH; Division of Hemato-Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Shin DY; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Hong J; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Kim H; Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Kim HJ; Division of Hematology/Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Zang DY; Division of Hematology/Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Yoon SS; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Jin JY; Division of Hemato-Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, Bucheon, Korea.
Lee JH; Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Hong DS; Division of Hemato-Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Park SK; Division of Hemato-Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2020 Aug 06; Vol. 15 (8), pp. e0235503. Date of Electronic Publication: 2020 Aug 06 (Print Publication: 2020).

Typ publikacji:

Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

MeSH Terms:

Antimetabolites, Antineoplastic/*administration & dosage
Decitabine/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Remission Induction/*methods
Age Factors ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/adverse effects ; Blood Cell Count ; Bone Marrow/pathology ; Decitabine/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Leukemia, Myeloid, Acute/blood ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Nutrition Assessment ; Progression-Free Survival ; Republic of Korea/epidemiology ; Retrospective Studies ; Weight Loss

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 45.

Tytuł:

Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.

Autorzy:

Palmieri R; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.
Buckley SA; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.
Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Halpern AB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Percival MM; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Scott BL; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Hendrie PC; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Seattle Cancer Care Alliance, Seattle, WA, USA.
Becker PS; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Oehler VG; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Estey EH; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Department of Pathology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2020 Jul; Vol. 61 (7), pp. 1728-1731. Date of Electronic Publication: 2020 Feb 20.

Typ publikacji:

Clinical Trial, Phase I; Letter; Randomized Controlled Trial; Research Support, N.I.H., Extramural

MeSH Terms:

Cladribine*/therapeutic use
Cytarabine*/therapeutic use
Decitabine*/therapeutic use
Granulocyte Colony-Stimulating Factor*/therapeutic use
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Mitoxantrone*/therapeutic use
Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Treatment Outcome

Raport

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 46.

Tytuł:

Decitabine limits escape from MEK inhibition in uveal melanoma.

Autorzy:

Gonçalves J; The Department of Tumor Biology, Moffitt Cancer Center, Tampa, FL, USA.; Departamento de Ciências Básicas da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.
Emmons MF; The Department of Tumor Biology, Moffitt Cancer Center, Tampa, FL, USA.
Faião-Flores F; The Department of Tumor Biology, Moffitt Cancer Center, Tampa, FL, USA.
Aplin AE; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Harbour JW; Bascom Palmer Eye Institute, Sylvester Comprehensive Cancer Center and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Licht JD; Division of Hematology & Oncology, Department of Medicine, University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.
Wink MR; Departamento de Ciências Básicas da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.
Smalley KSM; The Department of Tumor Biology, Moffitt Cancer Center, Tampa, FL, USA.

Pokaż więcej

Źródło:

Pigment cell & melanoma research [Pigment Cell Melanoma Res] 2020 May; Vol. 33 (3), pp. 507-514. Date of Electronic Publication: 2019 Dec 06.

Typ publikacji:

Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

MeSH Terms:

Decitabine/*therapeutic use
Melanoma/*drug therapy
Melanoma/*enzymology
Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Uveal Neoplasms/*drug therapy
Uveal Neoplasms/*enzymology
Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cell Line, Tumor ; Decitabine/pharmacology ; Female ; Humans ; Melanoma/pathology ; Mice ; Pyridones/pharmacology ; Pyridones/therapeutic use ; Pyrimidinones/pharmacology ; Pyrimidinones/therapeutic use ; Uveal Neoplasms/pathology ; Xenograft Model Antitumor Assays

SCR Disease Name:

Uveal melanoma

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 47.

Tytuł:

Inactivation of ZSCAN18 by promoter hypermethylation drives the proliferation via attenuating TP53INP2-mediated autophagy in gastric cancer cells.

Autorzy:

Li B; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Ren B; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China. .; Department of Gastroenterology and Pancreatic Surgery, ShanXi Provincial People's Hospital, Taiyuan, 030000, People's Republic of China. .
Ma G; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Cai F; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Wang P; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Zeng Y; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Liu Y; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Zhang L; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Yang Y; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Liang H; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Zhang R; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Deng J; Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China. .

Pokaż więcej

Źródło:

Clinical epigenetics [Clin Epigenetics] 2023 Jan 17; Vol. 15 (1), pp. 10. Date of Electronic Publication: 2023 Jan 17.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Autophagy*/genetics
Nuclear Proteins*/genetics
Stomach Neoplasms*/pathology
DNA-Binding Proteins*/genetics
Humans ; Cell Line, Tumor ; Cell Proliferation ; Decitabine/pharmacology ; DNA Methylation ; Gene Expression Regulation, Neoplastic ; Transcription Factors/genetics ; Transcription Factors/metabolism ; Promoter Regions, Genetic

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 48.

Tytuł:

The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment.

Autorzy:

Patties I; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany. .
Kallendrusch S; Institute of Anatomy, University of Leipzig, Liebigstraße 13, 04103, Leipzig, Germany.
Böhme L; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany.
Kendzia E; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany.
Oppermann H; Department of Neurosurgery, University of Leipzig, Liebigstraße 20, 04103, Leipzig, Germany.
Gaunitz F; Department of Neurosurgery, University of Leipzig, Liebigstraße 20, 04103, Leipzig, Germany.
Kortmann RD; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany.
Glasow A; Department of Radiooncology, University of Leipzig, Stephanstraße 9a, 04103, Leipzig, Germany.

Pokaż więcej

Źródło:

Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2019 Oct 21; Vol. 38 (1), pp. 420. Date of Electronic Publication: 2019 Oct 21.

Typ publikacji:

Journal Article

MeSH Terms:

Antineoplastic Agents, Alkylating/*therapeutic use
Cyclin-Dependent Kinase Inhibitor p21/*metabolism
Decitabine/*therapeutic use
Glioblastoma/*drug therapy
Glioblastoma/*radiotherapy
Radiotherapy/*methods
Temozolomide/*therapeutic use
Animals ; Antineoplastic Agents, Alkylating/pharmacology ; Cell Line, Tumor ; Decitabine/pharmacology ; Glioblastoma/pathology ; Humans ; Mice ; Temozolomide/pharmacology

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 49.

Tytuł:

Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.

Autorzy:

Li X; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Dong Y; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li Y; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ren R; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.
Wu W; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhu H; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhang Y; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China.; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hu J; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China. .; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .
Li J; Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin No.2 Road, Shanghai, 200025, People's Republic of China. .; Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .

Pokaż więcej

Źródło:

BMC cancer [BMC Cancer] 2019 Aug 20; Vol. 19 (1), pp. 819. Date of Electronic Publication: 2019 Aug 20.

Typ publikacji:

Clinical Trial, Phase II; Journal Article

MeSH Terms:

Fetal Blood*
Antimetabolites, Antineoplastic/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Blood Transfusion/*methods
Consolidation Chemotherapy/*methods
Cytarabine/*therapeutic use
Decitabine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Cytarabine/administration & dosage ; Decitabine/administration & dosage ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Prospective Studies ; Survival Rate

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 50.

Tytuł:

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.

Autorzy:

Kalinkova L; Department of Genetics, Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
Sevcikova A; Department of Genetics, Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
Stevurkova V; Department of Genetics, Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
Fridrichova I; Department of Genetics, Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
Ciernikova S; Department of Genetics, Cancer Research Institute, Biomedical Research Center of Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2022 Dec 30; Vol. 24 (1). Date of Electronic Publication: 2022 Dec 30.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Myelodysplastic Syndromes*/diagnosis
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/genetics
Leukemia*/diagnosis
Leukemia*/drug therapy
Leukemia*/genetics
Hematologic Neoplasms*/genetics
Lymphoma*/diagnosis
Lymphoma*/drug therapy
Lymphoma*/genetics
Humans ; DNA Methylation ; Decitabine ; Epigenesis, Genetic ; Prognosis ; Azacitidine/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły